Laboratorios Farmaceuticos Rovi, S.A./ADR
LABFFNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for LABFF. That does not mean none is planned.
Get an email about LABFF's next catalysts
Track Laboratorios Farmaceuticos Rovi, S.A./ADR (LABFF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DMMET-01 | Phase 3 | Diabetes Type 2 | - | - |
Nimotuzumab | Phase 2 | Diffuse Intrinsic Brainstem Gliomas | - | - |
Frequently asked questions
What is in Laboratorios Farmaceuticos Rovi, S.A./ADR's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Laboratorios Farmaceuticos Rovi, S.A./ADR's (LABFF) pipeline across Phase 3, Phase 2. Its lead program is DMMET-01 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Laboratorios Farmaceuticos Rovi, S.A./ADR's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Laboratorios Farmaceuticos Rovi, S.A./ADR (LABFF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LABFF biotech catalysts?→
Add LABFF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Laboratorios Farmaceuticos Rovi, S.A./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.